Modified insulinotropic peptides are disclosed. The modified insulinotropic
peptides are capable of forming a peptidase stabilized insulinotropic peptide.
The modified insulinotropic peptides are capable of forming covalent bonds with
one or more blood components to form a conjugate. The conjugates may be formed
in vivo or ex vivo. The modified peptides are administered to treat humans with
diabetes and other related diseases.
